Q-omics provides the consensus-scored FDPSP8 profile across patient tissues and cancer cell-line models. FDPSP8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FDPSP8 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, FDPSP8 RNA expression shows 14,873 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where FDPSP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FDPSP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FDPSP8 survival associations across molecular data types. FDPSP8 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FDPSP8 RNA expression–survival associations across cancer types. High FDPSP8 expression shows unfavorable associations in ACC, MESO, KIRC, LUAD, LIHC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FDPSP8 RNA expression.
This table summarizes FDPSP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FDPSP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FDPSP8 shows higher tumor expression in COAD, HNSC, LUSC, BRCA, BLCA and LIHC. The COAD box plot shows higher FDPSP8 RNA expression in tumor versus normal tissue (log2 FC = +0.339, t-test p < 0.001).
This table shows molecular features associated with FDPSP8 in patient tissues and cancer cell lines. In patient samples, FDPSP8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
